Staff Members - Benha University
Suprachoroidal triamcinolone acetonide injection: a novel therapy for serous retinal detachment due to Vogt-Koyanagi Harada disease
European Journal of Ophthalmology • 2022
Publication Information
Authors
Ahmed Abdelshafy Tabl, Mohamed Anany Elsayed, Marwa Abdelshafy Tabl
Keywords
Not Available
Journal
European Journal of Ophthalmology
Publisher
Sage journals
Volume
Not Available
Issue
Online first
Pages
7
publication.type
International
Paper Link
Open Link
Supplementary Materials
Not Available
Abstract
To assess the efficacy and safety of Suprachoroidal triamcinolone acetonide injection [SCTA] as an adjunctive therapy in management of Vogt-Koyanagi Harada [VKH] serous retinal detachment.
Design
Prospective parallel group study.
Participants
12 eyes of 6 patients with bilateral multiple serous retinal detachment of VKH in acute phase on systemic steroids.
Methods
Each patient was received single SCTA injection (SCTA group, n = 6 eyes) and the other non-injected eye (Standard treatment group, n = 6 eyes), patients were followed for 1, 3, and 6 months to assess changes in best corrected visual acuity [BCVA], central foveal thickness [CFT] and intraocular pressure [IOP] between both groups.
Main outcome measures
The primary end point was changes in BCVA from baseline till 6th months follow-up. Secondary end points were changes in CFT and IOP from baseline to 6 months of follow-up
Design
Prospective parallel group study.
Participants
12 eyes of 6 patients with bilateral multiple serous retinal detachment of VKH in acute phase on systemic steroids.
Methods
Each patient was received single SCTA injection (SCTA group, n = 6 eyes) and the other non-injected eye (Standard treatment group, n = 6 eyes), patients were followed for 1, 3, and 6 months to assess changes in best corrected visual acuity [BCVA], central foveal thickness [CFT] and intraocular pressure [IOP] between both groups.
Main outcome measures
The primary end point was changes in BCVA from baseline till 6th months follow-up. Secondary end points were changes in CFT and IOP from baseline to 6 months of follow-up